Literature DB >> 8589151

Tuberculosis in drug users.

D C Perlman1, N Salomon, M P Perkins, S Yancovitz, D Paone, D C Des Jarlais.   

Abstract

The rise in tuberculosis (TB) has disproportionately affected specific populations. Historically, many patients with TB became iatrogenic opiate addicts through therapeutic use of these drugs for symptom control. Demographic trends reshaped the relationship between drug use and TB into one in which drug use became a risk factor for tuberculosis as a result of the overlap of epidemiological and social factors associated with both drug use and TB. The spread of human immunodeficiency virus infection has amplified the spread of TB among drug users. We review the epidemiology of TB in drug users as well as the factors relevant to screening and compliance in drug-using populations. Drug users constitute a high-risk group for whom screening, prevention of infection, diagnosis, and treatment pose particular challenges. The development of TB services capable of engaging drug users (those both in and out of drug treatment programs) has potential for disrupting a significant chain of rapid TB transmission.

Entities:  

Mesh:

Year:  1995        PMID: 8589151     DOI: 10.1093/clinids/21.5.1253

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

2.  No butts about it: public smoking ends in Vermont.

Authors:  J K Carney; M C Hamrell; W E Wargo
Journal:  Am J Public Health       Date:  1997-05       Impact factor: 9.308

3.  Causes and costs of hospitalization of tuberculosis patients in the United States.

Authors:  Z Taylor; S M Marks; N M Ríos Burrows; S E Weis; R L Stricof; B Miller
Journal:  Int J Tuberc Lung Dis       Date:  2000-10       Impact factor: 2.373

4.  Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto.

Authors:  I D Rusen; L Yuan; M E Millson
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

5.  Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.

Authors:  D C Perlman; M N Gourevitch; C Trinh; N Salomon; L Horn; D C Des Jarlais
Journal:  J Urban Health       Date:  2001-09       Impact factor: 3.671

Review 6.  Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections.

Authors:  Sabita Roy; Jana Ninkovic; Santanu Banerjee; Richard Gene Charboneau; Subhas Das; Raini Dutta; Varvara A Kirchner; Lisa Koodie; Jing Ma; Jingjing Meng; Roderick A Barke
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-26       Impact factor: 4.147

7.  Counting the homeless: a previously incalculable tuberculosis risk and its social determinants.

Authors:  Marsha L Feske; Larry D Teeter; James M Musser; Edward A Graviss
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

Review 8.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

9.  Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing.

Authors:  David C Perlman; Patricia Friedmann; Leslie Horn; Anne Nugent; Veronika Schoeb; Jeanne Carey; Nadim Salomon; Don C Des Jarlais
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

10.  Influences of cross-border mobility on tuberculosis diagnoses and treatment interruption among injection drug users in Tijuana, Mexico.

Authors:  Robert Deiss; Richard S Garfein; Remedios Lozada; Jose Luis Burgos; Kimberly C Brouwer; Kathleen S Moser; Maria Luisa Zuniga; Timothy C Rodwell; Victoria D Ojeda; Steffanie A Strathdee
Journal:  Am J Public Health       Date:  2009-06-18       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.